<DOC>
	<DOCNO>NCT01211002</DOCNO>
	<brief_summary>It trials evaluate overall survival ( OS ) radiotherapy / EP combine recombinant human endostatin treatment locally advance ( Ⅲ A / unresectable Ⅲ B ) non-small cell lung cancer .</brief_summary>
	<brief_title>Study Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin Local Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . Patients pathologically histologically confirm inoperable stage Ⅲ ( Ⅲ A unresectable Ⅲ B ) NSCLC ; 2 . Patients age 18~70 year , general condition ECOG performance scale （PS）≤ 1 , weight loss &lt; 10 % last 6 month ; 3 . CT film patient last 4 week accessible patient select group , lesion measurable ; ( According standard RECIST1.1 , least one accurately measurable lesion large diameter ≥ 10mm spiral CT , PETCT , large diameter≥ 20mm ordinary CT MRI.） 4 . No major organ dysfunction , function heart , liver kidney normal , laboratory indicator meet following requirement : Blood : WBC &gt; 4.0 × 109 / L , absolute neutrophil count &gt; 1.5 × 109 / L , platelet count &gt; 100 × 109 / L , hemoglobin &gt; 110g / L ; liver function : serum bilirubin le 1.5 × maximum normal value ; ALT AST le 1.5 × maximum normal value ; BUN , Cr within normal range ; FEV1 &gt; 1L &gt; 40 % predict value ; 5 . Patients could understand circumstance study sign informed consent form ; 1 . Pregnant lactating woman ; woman childbearing age without contraception ; 2 . Acute infection serious underlying disease ; 3 . Significant neurological , psychiatric history , include dementia may influence ability understand inform consent ; 4 . Receive treatment experimental trial period ; medication anticancer drug time ; join drug clinical trial 30 day clinical trial ; 5 . Diabetes without control ( bloodglucose unstable ≥ 8mol / L administration ) ; 6 . Patients allergic E. coli preparation ; 7 . Patients unsuitable participate trial determine researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>rh-endostatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>NSCLC</keyword>
</DOC>